コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 Mortality analysis used the Kaplan Meier method.
2 ed on the basis of TCNs and stage, using the Kaplan-Meier method.
3 on to seroreversion, was estimated using the Kaplan-Meier method.
4 Overall survival was calculated by the Kaplan-Meier method.
5 Event rates were estimated using the Kaplan-Meier method.
6 Survival analysis was performed using the Kaplan-Meier method.
7 e-matched population was conducted using the Kaplan-Meier method.
8 DFS was calculated using the Kaplan-Meier method.
9 rvival (EFS) and OS were estimated using the Kaplan-Meier method.
10 and prognostic factors were tested with the Kaplan-Meier method.
11 erall survival (OS) were estimated using the Kaplan-Meier method.
12 Survival was calculated by using the Kaplan-Meier method.
13 or published results over time by using the Kaplan-Meier method.
14 ansplantation survival was assessed with the Kaplan-Meier method.
15 idelines, and survival was assessed with the Kaplan-Meier method.
16 t-failure-free survival was estimated by the Kaplan-Meier method.
17 nontissue valves was compared by use of the Kaplan-Meier method.
18 Overall survival was analyzed by using the Kaplan-Meier method.
19 continuation rates were calculated using the Kaplan-Meier method.
20 hose eligible for lifetime coverage with the Kaplan-Meier method.
21 Survival rates were assessed using the Kaplan-Meier method.
22 Median survival was calculated by using the Kaplan-Meier method.
23 lative risks (CRs) were calculated using the Kaplan-Meier method.
24 ired t tests, and OS was calculated with the Kaplan-Meier method.
25 Time to mastectomy was estimated using the Kaplan-Meier method.
26 Fidelis lead survival was analyzed by the Kaplan-Meier method.
27 me-to-event analysis was performed using the Kaplan-Meier method.
28 progression-free survival were estimated by Kaplan-Meier method.
29 Survival was analyzed using Kaplan-Meier method.
30 t was overall survival (OS), assessed by the Kaplan-Meier method.
31 vival probabilities were estimated using the Kaplan-Meier method.
32 he overall survival rate was estimated using Kaplan-Meier method.
33 more than 30 days after resection using the Kaplan-Meier method.
34 Overall survival (OS) was estimated by the Kaplan-Meier method.
35 Survival was estimated using the Kaplan-Meier method.
36 ial rates of LR were calculated by using the Kaplan-Meier method.
37 rence probabilities were estimated using the Kaplan-Meier method.
38 or progression-free survival outcomes by the Kaplan-Meier method.
39 Survival was estimated using the Kaplan-Meier method.
40 ating complications were estimated using the Kaplan-Meier method.
41 verall survival (OS) was estimated using the Kaplan-Meier method.
42 Overall survival was calculated using the Kaplan-Meier method.
43 ific (BCS) mortality were estimated with the Kaplan-Meier method.
44 erall survival also was comparable using the Kaplan-Meier method.
45 mined by Cox proportional hazards models and Kaplan-Meier method.
46 erall survival (OS) were estimated using the Kaplan-Meier method.
47 fidence intervals were computed by using the Kaplan-Meier method.
48 (OS) survival rates were analyzed using the Kaplan-Meier method.
49 erall survival (OS) were conducted using the Kaplan-Meier method.
50 e risk estimates were obtained by use of the Kaplan-Meier method.
51 hese cardiac diagnoses were estimated by the Kaplan-Meier method.
52 ase-specific survival were determined by the Kaplan-Meier method.
53 lated from the time of hepatectomy using the Kaplan-Meier method.
54 al treatment, estimated within groups by the Kaplan-Meier method.
55 lative hazard of AML was estimated using the Kaplan-Meier method.
56 ss survival times were computed by using the Kaplan-Meier method.
57 Results were analyzed with the Kaplan-Meier method.
58 Survival was calculated by the Kaplan-Meier method.
59 and survival curves were estimated using the Kaplan-Meier method.
60 nd 10-year survival was calculated using the Kaplan-Meier method.
61 Median survival was estimated using the Kaplan-Meier method.
62 Survival curves were derived using the Kaplan-Meier method.
63 Survival estimates were obtained by the Kaplan-Meier method.
64 Survival was estimated with the Kaplan-Meier method.
65 Survival was estimated using the Kaplan-Meier method.
66 Survival data were analyzed by using the Kaplan-Meier method.
67 or a related disorder, as assessed with the Kaplan-Meier method.
68 Survival rates were calculated using the Kaplan-Meier method.
69 Survival was described using the Kaplan-Meier method.
70 following diagnosis was estimated using the Kaplan-Meier method.
71 reatment failures) was assessed by using the Kaplan-Meier method.
72 s, and survival curves were estimated by the Kaplan-Meier method.
73 val probabilities were computed by using the Kaplan-Meier method.
74 ee survivals (RFS) were calculated using the Kaplan-Meier method.
75 cer-specific survival were calculated by the Kaplan-Meier method.
76 recurrence survival was calculated using the Kaplan-Meier method.
77 calculated from the time of RFA by using the Kaplan-Meier method.
78 Survival outcomes were estimated by the Kaplan-Meier method.
79 rmation-free, and overall survival) with the Kaplan-Meier method.
80 ysed data for response and survival with the Kaplan-Meier method.
81 Survival outcomes were estimated by the Kaplan-Meier method.
82 sease-free survival were estimated using the Kaplan-Meier method.
83 erall survival (OS) were estimated using the Kaplan-Meier method.
84 -free survival analysis was assessed using a Kaplan-Meier method.
85 Survival was assessed using the Kaplan-Meier method.
86 PFS/DFS and OS were estimated by the Kaplan-Meier method.
87 in the 2 matched groups was analyzed by the Kaplan-Meier method.
88 OS rates were estimated using the Kaplan-Meier method.
89 -related mortality were calculated using the Kaplan-Meier method.
90 ulative incidence of PCO was estimated using Kaplan-Meier methods.
91 ates of discontinuation were estimated using Kaplan-Meier methods.
92 , class 2 obesity, and severe obesity) using Kaplan-Meier methods.
93 Survival and fBOS were estimated with Kaplan-Meier methods.
94 s test for correlated binary proportions and Kaplan-Meier methods.
95 Survival rates were estimated by using Kaplan-Meier methods.
96 The observed mortality was estimated using Kaplan-Meier methods.
97 Survival was computed using Kaplan-Meier methods.
98 p to 20 years of age was estimated by use of Kaplan-Meier methods.
99 arial estimates for OS were calculated using Kaplan-Meier methods.
100 ipped of patient identifiers and analyzed by Kaplan-Meier methods.
101 lly meaningful deterioration was analysed by Kaplan-Meier methods.
102 rimary end point was 6-month PFS assessed by Kaplan-Meier methods.
104 301 consecutive patients with ARVC using the Kaplan-Meier method adjusted to avoid the bias of delaye
107 doubling time were analyzed by means of the Kaplan-Meier method and analysis of variance statistics.
108 by treatment cohort was estimated using the Kaplan-Meier method and analyzed using the log rank test
115 RFS and survival were estimated by using the Kaplan-Meier method and compared by using the log-rank t
116 We estimated risk of CRC over time by the Kaplan-Meier method and compared immigrants to controls
117 erall survival (OS) were described using the Kaplan-Meier method and compared using log-rank test.
120 OS) according to TRG were assessed using the Kaplan-Meier method and compared using the log-rank test
121 rall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test
122 erall survival curves were constructed using Kaplan-Meier method and compared via stratified log-rank
123 ients matched by propensity scores using the Kaplan-Meier method and Cox models in "intention-to-trea
125 between patients with and without RVAD using Kaplan-Meier method and Cox proportional hazards modelin
126 sion or recurrence) were evaluated using the Kaplan-Meier method and Cox proportional hazards modelin
127 n-free survival (PFS) was analyzed using the Kaplan-Meier method and Cox proportional hazards modelin
128 g the first 5 years posttransplant using the Kaplan-Meier method and Cox proportional hazards models.
130 erall survival times were examined using the Kaplan-Meier method and Cox proportional hazards regress
131 ase-specific survival were analyzed with the Kaplan-Meier method and Cox proportional hazards regress
139 pericarditis predicts cancer survival by the Kaplan-Meier method and Cox regression using a matched c
145 wn prognostic factors were calculated by the Kaplan-Meier method and evaluated with the log-rank test
146 egional control (LRC) were calculated by the Kaplan-Meier method and evaluated with the log-rank test
149 Univariate analysis was performed with the Kaplan-Meier method and log-rank test, and multivariate
153 [CS]) on PFS and OS were assessed using the Kaplan-Meier method and multivariable regression analysi
158 ulative survival were evaluated by using the Kaplan-Meier method and survival curves were plotted.
163 rtality and as long-term mortality using the Kaplan-Meier method and using standardized mortality rat
164 Survival curves were generated using the Kaplan-Meier method and were compared by log-rank analys
165 erall survival (OS) rates were determined by Kaplan-Meier method and were compared by using the log-r
166 t were evaluated and calculated by using the Kaplan-Meier method and were compared by using the log-r
167 ival (PFS) rates were estimated by using the Kaplan-Meier method and were compared by using the one-s
168 3 years postoperatively was estimated using Kaplan-Meier methods and compared to the 5-year incidenc
173 he risk of HIV infection was estimated using Kaplan-Meier methods and hazard ratios from proportional
176 r-specific survival were generated using the Kaplan-Meier method, and a Cox proportional hazards mode
177 e-free survival (DFS) were calculated by the Kaplan-Meier method, and a simplified QTNM score was dev
178 of each type of violence was modeled by the Kaplan-Meier method, and Cox hazard models with time-var
179 Survival outcomes were estimated by the Kaplan-Meier method, and Cox models were fit to determin
183 verall survival (OS) was estimated using the Kaplan-Meier method, and disease-specific survival (DSS)
185 cific survival (OS) was calculated using the Kaplan-Meier method, and hypothetical differences were c
186 Long-term survival was estimated by the Kaplan-Meier method, and independent predictors of morta
188 pairs signed-rank test, life-table analysis, Kaplan-Meier method, and log-rank test, as appropriate.
191 Survival estimates were calculated using the Kaplan-Meier method, and multivariable analysis was cond
192 tomy (RP), using descriptive statistics, the Kaplan-Meier method, and multivariable Cox proportional
193 Survival probability was calculated by the Kaplan-Meier method, and prognostic variables were analy
194 ward attainment were calculated by using the Kaplan-Meier method, and sex differences were assessed b
195 overall survival (OS) were estimated by the Kaplan-Meier method, and the association of HPV DNA dete
197 ong-term complications, determined using the Kaplan-Meier method, and the relation to mitomycin conce
200 FS and OS were estimated univariately by the Kaplan-Meier method, and treatment arms were compared by
201 and control groups were estimated using the Kaplan-Meier method, and were tested for equality by the
202 The risk of relapse was calculated using Kaplan-Meier methods, and predictors were determined usi
204 estimated the distribution of TFS using the Kaplan-Meier method, assessing between-group differences
207 fidence intervals (CIs) were estimated using Kaplan-Meier methods at 3, 12, and 36 months after treat
208 r transplantation was estimated by using the Kaplan-Meier method compared with log-rank tests and mod
209 Receiver operating characteristic curve, Kaplan-Meier method, Cox regression, and classification
210 P-free and survival rates were assessed with Kaplan-Meier method; differences between groups assessed
211 ll survival, TTP, and PFS were analyzed with Kaplan-Meier method; differences were compared with log-
216 Cumulative event rates were estimated by the Kaplan-Meier method; hazard ratios were calculated with
221 stimating survival probabilities, namely the Kaplan-Meier method, is suboptimal in the analysis of de
224 s performed include survival analysis by the Kaplan-Meier method, log-rank test, and Cox proportional
228 the unadjusted survival probabilities of the Kaplan-Meier method nor their adjustment for prognostic
229 s-free survival (DMFS) was calculated by the Kaplan-Meier method; predictors of outcome were identifi
232 ssion to HG-IEN/BAc was calculated using the Kaplan-Meier method; the Cox regression model was used t
233 ause-specific survival were calculated using Kaplan-Meier methods; the log-rank test was used to comp
235 We used stepwise Cox regression and the Kaplan-Meier method to assess variables obtained at base
236 ts in the full analysis set predicted by the Kaplan-Meier method to be seizure-free at 6 months was 9
242 mor levels of EGFR with tumor stage, and the Kaplan-Meier method to estimate patients' median surviva
244 999 through 2002 were analyzed by use of the Kaplan-Meier method to estimate risks of pregnancy loss
247 to first development of PDR was analyzed by Kaplan-Meier methods to calculate cumulative probabiliti
249 mpact on median overall survival (OS) by the Kaplan-Meier method, univariate analysis (log-rank test)
254 ata were analyzed by intention to treat; the Kaplan-Meier method was used to assess 5-year event rate
269 ion probability at 7 years (estimated by the Kaplan-Meier method) was 10.5% (95% CI, 6.8% to 16.1%).
270 The acute rejection free rate at study end (Kaplan-Meier method) was 55.5% for patients on tacrolimu
274 redicted by the nomogram and observed by the Kaplan-Meier method were similar at 3- and 5-year for pa
283 adjusted Cox proportional hazards models and Kaplan-Meier methods were used to estimate the effect of
286 cumulative incidence was estimated using the Kaplan-Meier method with age at onset as the time variab
287 calculated age-related penetrance using the Kaplan-Meier method with data for 603 individuals with t
288 state cancer survival was examined using the Kaplan-Meier method with deaths from other causes treate
290 eriod after the index prescription using the Kaplan-Meier method with log-rank test and stepwise regr
291 -to-event analyses were calculated using the Kaplan-Meier method with log-rank test for comparisons.
297 analyses of potential prognostic variables (Kaplan-Meier method with two-tailed log-rank test and Co
298 , long-term survival was evaluated using the Kaplan-Meier method, with comparisons based on the log-r
299 ase-free survivals were determined using the Kaplan-Meier method, with differences determined by mult
300 Survival analyses were performed using the Kaplan-Meier method, with the differences in survival cu
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。